SCM
CORT icon

Soleus Capital Management’s Corcept Therapeutics CORT Stock Holding History

Soleus Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Sell
19,653
-265,878
-93% -$16.1M 0.06% 85
2026
Q1 		$11.5M Buy
+285,531
New +$10.7M 0.47% 45
2021
Q4 		– Sell
-155,000
Closed -$3.05M – 75
2021
Q3 		$3.05M Buy
+155,000
New +$3.24M 0.48% 52

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Soleus Capital Management's CORT Position: Q2 2026 in Review

Soleus Capital Management reduced its Corcept Therapeutics (CORT) stake by 93% in Q2 2026, selling an estimated $16.1M and leaving 19,653 shares worth $1.71M. The position accounts for 0.06% of the portfolio, ranked #85.

Soleus Capital Management first reported a position in CORT in Q3 2021 and has held it in 3 quarters since. The position peaked at $11.5M in Q1 2026. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Soleus Capital Management held 19,653 shares of Corcept Therapeutics worth $1.71M as of Q2 2026.
  • Soleus Capital Management sold 265,878 Corcept Therapeutics shares in Q2 2026, an estimated $16.1M.
  • Corcept Therapeutics made up 0.06% of Soleus Capital Management's portfolio in Q2 2026, its #85 holding.
  • Soleus Capital Management first reported a position in Corcept Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • Soleus Capital Management's Corcept Therapeutics position peaked at $11.5M in Q1 2026.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.